Haddad, R., Concha‐Benavente, F., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., . . . Ferris, R. L. (2019). Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer.
Chicago Style aipamenaHaddad, Robert, et al. "Nivolumab Treatment Beyond RECIST‐defined Progression in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck in CheckMate 141: A Subgroup Analysis of a Randomized Phase 3 Clinical Trial." Cancer 2019.
MLA aipamenaHaddad, Robert, et al. "Nivolumab Treatment Beyond RECIST‐defined Progression in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck in CheckMate 141: A Subgroup Analysis of a Randomized Phase 3 Clinical Trial." Cancer 2019.